Mylan (MYL) Rating Increased to Buy at Argus
Argus upgraded shares of Mylan (NASDAQ:MYL) from a hold rating to a buy rating in a report issued on Thursday, Marketbeat.com reports. They currently have $42.00 price target on the stock.
Other equities analysts have also recently issued research reports about the stock. Mizuho reiterated a buy rating and set a $54.00 price target on shares of Mylan in a research report on Wednesday, August 8th. Citigroup reduced their price target on shares of Mylan from $50.00 to $48.00 and set a buy rating on the stock in a research report on Thursday, August 9th. Bank of America raised shares of Mylan from a neutral rating to a buy rating and dropped their price objective for the stock from $44.00 to $42.00 in a research note on Tuesday, November 6th. Royal Bank of Canada dropped their price objective on shares of Mylan from $51.00 to $50.00 and set a buy rating on the stock in a research note on Tuesday, November 6th. Finally, Wells Fargo & Co raised shares of Mylan from a market perform rating to a buy rating and set a $40.00 price objective on the stock in a research note on Tuesday, November 6th. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and fourteen have assigned a buy rating to the company. The company currently has an average rating of Buy and an average price target of $46.56.
Shares of NASDAQ MYL opened at $34.92 on Thursday. Mylan has a 1 year low of $30.33 and a 1 year high of $47.82. The company has a debt-to-equity ratio of 1.20, a quick ratio of 0.77 and a current ratio of 1.26. The stock has a market cap of $18.01 billion, a P/E ratio of 7.66, a P/E/G ratio of 1.15 and a beta of 1.53.
Hedge funds and other institutional investors have recently modified their holdings of the company. First Mercantile Trust Co. bought a new position in shares of Mylan in the second quarter worth approximately $121,000. Stratos Wealth Partners LTD. bought a new position in shares of Mylan in the third quarter worth approximately $183,000. FTB Advisors Inc. bought a new position in shares of Mylan in the second quarter worth approximately $188,000. Reilly Financial Advisors LLC lifted its stake in shares of Mylan by 69.4% in the third quarter. Reilly Financial Advisors LLC now owns 5,217 shares of the company’s stock worth $191,000 after buying an additional 2,137 shares in the last quarter. Finally, BB&T Corp bought a new position in shares of Mylan in the third quarter worth approximately $202,000. Hedge funds and other institutional investors own 81.91% of the company’s stock.
Mylan Company Profile
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, brand name, and over-the-counter (OTC) products worldwide. The company operates through three segments: North America, Europe, and Rest of World. It offers pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized, and cream or ointment forms.
Further Reading: Marijuana Stocks Investing Considerations
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.